Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

This study aims to enhance the classification accuracy of non-small cell lung cancer (NSCLC) histopathological images by proposing a novel deep-learning architecture that integrates convolutional ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Lung cancer has traditionally been associated with advanced age; however, its increasing incidence among young adults raises concerning questions regarding its etiology and unique considerations for ...

GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival ...

A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery for patients with aggressive stage III non-small cell lung cancer that is ...

Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA–IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB ...